查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1379650

韓國美容市場 - 產業趨勢與預測（截至 2030 年）

Korea Aesthetic Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 109 Pages | 商品交期: 請詢問到貨日

價格

韓國美容市場預計將從 2022 年的 2,260,540 美元增加到 2030 年的 7,962,270 美元，2023-2030 年預測期間複合年增長率為 17.3%。

本報告對韓國美容市場進行研究和分析，提供行業趨勢和預測、驅動和約束因素以及企業趨勢等資訊。

目錄

第 1 章 簡介

第二章 市場區隔

第三章執行摘要

第 4 章重要注意事項

  • PESTEL 分析
  • 波特五力分析

第五章韓國美容市場：監理框架

  • 進行整容手術的適當要求
  • 美容業對美容服務表現的監管
  • 美容相關醫療器材監管
  • 進行美容治療的門診機構的規定
  • 保護接受整容手術的個人

第六章市場概況

  • 促進者
    • 降低美容醫學的治療成本
    • 韓國醫療旅遊的興起
    • 提高醫學美容意識
    • 微創和非侵入性手術的使用增加
  • 抑制因素
    • 存在無執照的皮膚科醫生
    • 社會對美的偏見
    • 報銷不足的發展
  • 機會
    • 市場進入者的策略舉措
    • 加大研發力度
    • 美容技術的進步
  • 任務
    • 缺乏熟練的專業知識
    • 與使用真皮填充劑相關的副作用
    • 嚴格的產品批准

第七章 韓國美容市場：依設備分類

  • 概述
  • 非能源美容儀器
    • 肉毒桿菌毒素
    • 真皮填充劑、美容線
    • 注入
    • 微晶磨皮術
    • 化學換膚
    • 其他
  • 以能量為基礎的美容設備
    • 雷射美容設備
    • 超音波美容儀器
    • 基於射頻 (RF) 的美容設備
    • 光美容儀
    • 其他

第八章 韓國美容市場：依應用分類

  • 概述
  • 非手術的
    • 塑身
    • 非侵入性
    • 皮膚緊緻
    • 痤瘡治療
    • 脫髮
    • 去除紋身
    • 其他
  • 手術
    • 臉部和頭部手術
    • 胸部手術
    • 軀幹和四肢手術

第 9 章 韓國美容市場：依品牌分類

  • 概述
  • 肉毒桿菌毒素
    • NABOTA
    • BOTOX
    • BOTULAX
    • MEDITOXIN
    • XEOMIN
    • 其他
  • 真皮填充劑
    • JUVEDERM
    • RESTYLANE
    • BELOTERO
    • CHAEUM
    • 其他
  • 拉皮
    • INMODE
    • ULTHERA
    • ULTRAFORMER III
    • THERMAGE
    • 其他
  • 其他

第10章韓國美容市場：性別

  • 概述
  • 女士
  • 男性

第 11 章 韓國美容市場：依最終用戶分類

  • 概述
  • 皮膚科診所
  • 醫院
  • 專科診所
  • 醫療水療/美容中心
  • 其他

第十二章韓國美容市場：依通路分類

  • 概述
  • 直接報價
  • 零售

第13章韓國美容市場：企業狀況

  • 韓國美容市場（無全球基地）：企業狀況

第14章SWOT分析

第十五章公司簡介

  • ABBVIE INC.
  • DAEWOONG OPEN COLLABORATION
  • GALDERMA
  • CYNOSURE INC
  • LUTRONIC CORPORATION
  • AMIINC
  • BAUSCH HEALTH COMPANIES INC.
  • BISON MEDICAL
  • BLUECORE COMPANY
  • CANDELA CORPORATION
  • CLASSYS INC.
  • HUGEL, INC.
  • HIRONIC CO., LTD.
  • INMODE
  • MEDYTOX
  • MERZ NORTH AMERICA, INC. (A SUBSIDIARY OF MERZ PHARMA)
  • UNIONMEDICAL CO., LTD.
  • WEERO
  • WON TECH CO., LTD.

第16章調查

第十七章 相關報告

Korea aesthetics market is expected to reach USD 7,962.27 thousand by 2030 from USD 2,260.54 thousand in 2022, growing at a CAGR of 17.3% in the forecast period of 2023 to 2030.

Market Segmentation

Korea Aesthetics Market, By Device (Energy Based Aesthetic Devices, Non Energy Based Aesthetic Devices), By Application (Surgical, Non- Surgical), By Brands (Skin Lifting, Botulinum Toxin, Dermal Fillers), By Gender (Male, Female), By End-User (Hospitals, Specialty Clinics, Dermatology Clinics, Medical Spas and Beauty Centers, Others), By Distribution Channel (Direct Tender, Retail Sales), country (Korea) - Industry Trends and Forecast to 2030.

Overview of Korea Aesthetics Market Dynamics

  • Drivers
  • Less cost of aesthetic treatments in comparison to other countries.
  • Rise in medical tourism
  • Restrains
  • Strict regulatory guidelines
  • Opportunity
  • Strategic initiatives by market players

Market Players

The key market players for Korea Aesthetics market are listed below:

  • AbbVie Inc.
  • Daewoong Open Collaboration
  • Galderma
  • Cynosure Inc
  • Lutronic Corporation
  • Merz
  • HUGEL, Inc.
  • Medytox
  • INMODE
  • CLASSYS Inc.
  • Candela Medical
  • AMIINC
  • WON TECH Co., Ltd.
  • UNIONMEDICAL Co.,Ltd.
  • Bausch Health Companies Inc.
  • BISON MEDICAL
  • Bluecore Company
  • Hironic Co. Ltd.
  • WEERO

TABLE OF CONTENTS

1 INTRODUCTION 11

  • 1.1 OBJECTIVES OF THE STUDY 11
  • 1.2 MARKET DEFINITION 11
  • 1.3 OVERVIEW OF THE KOREA AESTHETIC MARKET 11
  • 1.4 CURRENCY AND PRICING 12
  • 1.5 LIMITATIONS 12
  • 1.6 MARKETS COVERED 13

2 MARKET SEGMENTATION 16

  • 2.1 MARKETS COVERED 16
  • 2.2 GEOGRAPHICAL SCOPE 17
  • 2.3 YEARS CONSIDERED FOR THE STUDY 17
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
  • 2.6 MULTIVARIATE MODELLING 22
  • 2.7 DEVICES SEGMENT LIFELINE CURVE 22
  • 2.8 MARKET END USER COVERAGE GRID 23
  • 2.9 DBMR MARKET POSITION GRID 24
  • 2.10 VENDOR SHARE ANALYSIS 26
  • 2.11 SECONDARY SOURCES 27
  • 2.12 ASSUMPTIONS 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 30

  • 4.1 PESTEL ANALYSIS 31
  • 4.2 PORTER'S FIVE FORCES 32

5 KOREA AESTHETIC MARKET: REGULATORY FRAMEWORK 33

  • 5.1 COMPETENT REQUIREMENTS TO PERFORM AESTHETIC PROCEDURES 33
  • 5.2 REGULATION OF THE BEAUTY DOMAIN FOR PERFORMING AESTHETIC SERVICES 33
  • 5.3 REGULATION OF COSMETIC-RELATED MEDICAL DEVICES 33
  • 5.4 REGULATION OF AMBULATORY AMENITIES WHERE THE AESTHETIC PROCEDURES ARE PERFORMED 34
  • 5.5 PROTECTION OF INDIVIDUALS UNDERGOING THE AESTHETIC PROCEDURE 34 

6 MARKET OVERVIEW 35

  • 6.1 DRIVERS 37
    • 6.1.1 LESSER COST OF TREATMENT FOR MEDICAL AESTHETICS 37
    • 6.1.2 RISE IN MEDICAL TOURISM IN KOREA 37
    • 6.1.3 INCREASING AWARENESS ABOUT MEDICAL AESTHETICS 37
    • 6.1.4 INCREASING USE OF MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 38
  • 6.2 RESTRAINTS 39
    • 6.2.1 PRESENCE OF UNLICENSED DERMATOLOGISTS 39
    • 6.2.2 SOCIAL STIGMA REGARDING AESTHETICS 39
    • 6.2.3 INADEQUATE REIMBURSEMENT DEVELOPMENT 40
  • 6.3 OPPORTUNITIES 41
    • 6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 41
    • 6.3.2 INCREASING RESEARCH AND DEVELOPMENT 41
    • 6.3.3 TECHNOLOGICAL ADVANCEMENTS FOR AESTHETIC TREATMENT 42
  • 6.4 CHALLENGES 42
    • 6.4.1 LACK OF SKILLED EXPERTISE 42
    • 6.4.2 SIDE EFFECTS ASSOCIATED WITH USE OF DERMAL FILLERS 42
    • 6.4.3 APPROVALS OF STRINGENT PRODUCTS 43

7 KOREA AESTHETIC MARKET, BY DEVICES 44

  • 7.1 OVERVIEW 45
  • 7.2 NON ENERGY BASED AESTHETIC DEVICES 46
    • 7.2.1 BOTULINUM TOXIN 46
    • 7.2.2 DERMAL FILLERS AND AESTHETIC THREADS 46
    • 7.2.3 IMPLANTS 46
    • 7.2.4 MICRODERMABRASION 47
    • 7.2.5 CHEMICAL PEELS 47
    • 7.2.6 OTHERS 47
  • 7.3 ENERGY BASED AESTHETIC DEVICES 47
    • 7.3.1 LASER BASED AESTHETIC DEVICES 47
    • 7.3.2 ULTRASOUND AESTHETIC DEVICES 47
    • 7.3.3 RADIOFREQUENCY (RF) BASED AESTHETIC DEVICES 48
    • 7.3.4 LIGHT BASED AESTHETIC DEVICES 48
    • 7.3.5 OTHERS 48 

8 KOREA AESTHETIC MARKET, BY APPLICATION 49

  • 8.1 OVERVIEW 50
  • 8.2 NON-SURGICAL 51
    • 8.2.1 BODY CONTOURING 51
    • 8.2.2 NON INVASIVE FAT REDUCTION 51
    • 8.2.3 SKIN TIGHTENING 51
    • 8.2.4 ACNE TREATMENTS 51
    • 8.2.5 HAIR REMOVAL 52
    • 8.2.6 TATTOO REMOVAL 52
    • 8.2.7 OTHERS 52
  • 8.3 SURGICAL 52
    • 8.3.1 FACE & HEAD SURGERY 52
      • 8.3.1.1 FACELIFT 53
      • 8.3.1.2 BROW LIFT 53
      • 8.3.1.3 FACIAL BONE CONTOURING 53
      • 8.3.1.4 NECK LIFT 53
      • 8.3.1.5 OTHERS 53
    • 8.3.2 BREAST SURGERY 53
      • 8.3.2.1 BREAST AUGMENTATION 53
      • 8.3.2.2 BREAST LIFT 53
    • 8.3.3 BODY & EXTREMITIES SURGERY 54
      • 8.3.3.1 LIPOSUCTION 54
      • 8.3.3.2 LOWER BODY LIFT 54
      • 8.3.3.3 THIGH LIFT 54
      • 8.3.3.4 UPPER ARM LIFT 54
      • 8.3.3.5 OTHERS 54

9 KOREA AESTHETIC MARKET, BY BRANDS 55

  • 9.1 OVERVIEW 56
  • 9.2 BOTULINUM TOXIN 57
    • 9.2.1 NABOTA 57
    • 9.2.2 BOTOX 57
    • 9.2.3 BOTULAX 57
    • 9.2.4 MEDITOXIN 58
    • 9.2.5 XEOMIN 58
    • 9.2.6 OTHERS 58 
  • 9.3 DERMAL FILLER 58
    • 9.3.1 JUVEDERM 58
    • 9.3.2 RESTYLANE 58
    • 9.3.3 BELOTERO 58
    • 9.3.4 CHAEUM 58
    • 9.3.5 OTHERS 59
  • 9.4 SKIN LIFTING 59
    • 9.4.1 INMODE 59
    • 9.4.2 ULTHERA 59
    • 9.4.3 ULTRAFORMER III 59
    • 9.4.4 THERMAGE 59
    • 9.4.5 OTHERS 59
  • 9.5 OTHERS 59

10 KOREA AESTHETIC MARKET, BY GENDER 60

  • 10.1 OVERVIEW 61
  • 10.2 FEMALE 62
  • 10.3 MALE 62

11 KOREA AESTHETIC MARKET, BY END USER 63

  • 11.1 OVERVIEW 64
  • 11.2 DERMATOLOGY CLINICS 65
  • 11.3 HOSPITALS 65
  • 11.4 SPECIALTY CLINICS 65
  • 11.5 MEDICAL SPAS & BEAUTY CENTERS 65
  • 11.6 OTHERS 65

12 KOREA AESTHETIC MARKET, BY DISTRIBUTION CHANNEL 66

  • 12.1 OVERVIEW 67
  • 12.2 DIRECT TENDER 68
  • 12.3 RETAIL SALES 68

13 KOREA AESTHETIC MARKET: COMPANY LANDSCAPE 69

  • 13.1 KOREA AESTHETIC MARKET (WITHOUT GLOBAL BASE): COMPANY LANDSCAPE 70

14 SWOT ANALYSIS 71

15 COMPANY PROFILE 72

  • 15.1 ABBVIE INC. 72
    • 15.1.1 COMPANY SNAPSHOT 72
    • 15.1.2 REVENUE ANALYSIS 72
    • 15.1.3 PRODUCT PORTFOLIO 73
    • 15.1.4 RECENT DEVELOPMENTS 73
  • 15.2 DAEWOONG OPEN COLLABORATION 75
    • 15.2.1 COMPANY SNAPSHOT 75
    • 15.2.2 REVENUE ANALYSIS 75
    • 15.2.3 PRODUCT PORTFOLIO 76
    • 15.2.4 RECENT DEVELOPMENTS 76
  • 15.3 GALDERMA 78
    • 15.3.1 COMPANY SNAPSHOT 78
    • 15.3.2 PRODUCT PORTFOLIO 78
    • 15.3.3 RECENT DEVELOPMENTS 78
  • 15.4 CYNOSURE INC 80
    • 15.4.1 COMPANY SNAPSHOT 80
    • 15.4.2 PRODUCT PORTFOLIO 80
    • 15.4.3 RECENT DEVELOPMENTS 81
  • 15.5 LUTRONIC CORPORATION 82
    • 15.5.1 COMPANY SNAPSHOT 82
    • 15.5.2 PRODUCT PORTFOLIO 82
    • 15.5.3 RECENT DEVELOPMENTS 82
  • 15.6 AMIINC 84
    • 15.6.1 COMPANY SNAPSHOT 84
    • 15.6.2 PRODUCT PORTFOLIO 84
    • 15.6.3 RECENT DEVELOPMENTS 84
  • 15.7 BAUSCH HEALTH COMPANIES INC. 85
    • 15.7.1 COMPANY SNAPSHOT 85
    • 15.7.2 REVENUE ANALYSIS 85
    • 15.7.3 PRODUCT PORTFOLIO 86
    • 15.7.4 RECENT DEVELOPMENTS 86
  • 15.8 BISON MEDICAL 87
    • 15.8.1 COMPANY SNAPSHOT 87
    • 15.8.2 PRODUCT PORTFOLIO 87
    • 15.8.3 RCENT DEVELOPMENTS 87
  • 15.9 BLUECORE COMPANY 89
    • 15.9.1 COMPANY SNAPSHOT 89
    • 15.9.2 PRODUCT PORTFOLIO 89
    • 15.9.3 RECENT DEVELOPMENTS 89
  • 15.10 CANDELA CORPORATION 90
    • 15.10.1 COMPANY SNAPSHOT 90
    • 15.10.2 PRODUCT PORTFOLIO 90
    • 15.10.3 RECENT DEVELOPMENT 90 
  • 15.11 CLASSYS INC. 91
    • 15.11.1 COMPANY SNAPSHOT 91
    • 15.11.2 PRODUCT PORTFOLIO 91
    • 15.11.3 RECENT DEVELOPMENTS 91
  • 15.12 HUGEL, INC. 92
    • 15.12.1 COMPANY SNAPSHOT 92
    • 15.12.2 REVENUE ANALYSIS 92
    • 15.12.3 PRODUCT PORTFOLIO 93
    • 15.12.4 RECENT DEVELOPMENTS 93
  • 15.13 HIRONIC CO., LTD. 94
    • 15.13.1 COMPANY SNAPSHOT 94
    • 15.13.2 PRODUCT PORTFOLIO 94
    • 15.13.3 RECENT DEVELOPMENTS 95
  • 15.14 INMODE 96
    • 15.14.1 COMPANY SNAPSHOT 96
    • 15.14.2 REVENUE ANALYSIS 96
    • 15.14.3 PRODUCT PORTFOLIO 97
    • 15.14.4 RECENT DEVELOPMENTS 97
  • 15.15 MEDYTOX 99
    • 15.15.1 COMPANY SNAPSHOT 99
    • 15.15.2 PRODUCT PORTFOLIO 99
    • 15.15.3 RECENT DEVELOPMENT 100
  • 15.16 MERZ NORTH AMERICA, INC. (A SUBSIDIARY OF MERZ PHARMA) 101
    • 15.16.1 COMPANY SNAPSHOT 101
    • 15.16.2 PRODUCT PORTFOLIO 101
    • 15.16.3 RECENT DEVELOPMENTS 101
  • 15.17 UNIONMEDICAL CO.,LTD. 103
    • 15.17.1 COMPANY SNAPSHOT 103
    • 15.17.2 PRODUCT PORTFOLIO 103
    • 15.17.3 RECENT DEVELOPMENTS 103
  • 15.18 WEERO 104
    • 15.18.1 COMPANY SNAPSHOT 104
    • 15.18.2 PRODUCT PORTFOLIO 104
    • 15.18.3 RECENT DEVELOPMENT 104
  • 15.19 WON TECH CO., LTD. 105
    • 15.19.1 COMPANY SNAPSHOT 105
    • 15.19.2 PRODUCT PORTFOLIO 105
    • 15.19.3 RECENT DEVELOPMENTS 105 

16 QUESTIONNAIRE 106

17 RELATED REPORTS 109

LIST OF TABLES

  • TABLE 1 KOREA AESTHETIC MARKET, BY DEVICES, 2021-2030 (USD MILLION) 46
  • TABLE 2 KOREA NON ENERGY BASED AESTHETIC DEVICES IN AESTHETIC MARKET, BY DEVICES, 2021-2030 (USD MILLION) 46
  • TABLE 3 KOREA ENERGY BASED AESTHETIC DEVICES IN AESTHETIC MARKET, BY DEVICES, 2021-2030 (USD MILLION) 47
  • TABLE 4 KOREA AESTHETIC MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 51
  • TABLE 5 KOREA NON- SURGICAL IN AESTHETIC MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 51
  • TABLE 6 KOREA SURGICAL IN AESTHETIC MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 52
  • TABLE 7 KOREA FACE & HEAD SURGERY IN AESTHETIC MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 52
  • TABLE 8 KOREA BREAST SURGERY IN AESTHETIC MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 53
  • TABLE 9 KOREA BODY & EXTREMITIES SURGERY IN AESTHETIC MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 54
  • TABLE 10 KOREA AESTHETIC MARKET, BY BRANDS, 2021-2030 (USD MILLION) 57
  • TABLE 11 KOREA BOTULINUM TOXIN IN AESTHETIC MARKET, BY BRANDS, 2021-2030 (USD MILLION) MILLION) 57
  • TABLE 12 KOREA DERMAL FILLER IN AESTHETIC MARKET, BY BRANDS, 2021-2030 (USD MILLION) 58
  • TABLE 13 KOREA SKIN LIFTING IN AESTHETIC MARKET, BY BRANDS, 2021-2030 (USD MILLION) 59
  • TABLE 14 KOREA AESTHETIC MARKET, BY GENDER, 2021-2030 (USD MILLION) 62
  • TABLE 15 KOREA AESTHETIC MARKET, BY END USER, 2021-2030 (USD MILLION) 65
  • TABLE 16 KOREA AESTHETIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 68

LIST OF FIGURES

  • FIGURE 1 KOREA AESTHETIC MARKET: SEGMENTATION 16
  • FIGURE 2 KOREA AESTHETIC MARKET: DATA TRIANGULATION 18
  • FIGURE 3 KOREA AESTHETIC MARKET: DROC ANALYSIS 19
  • FIGURE 4 KOREA AESTHETIC MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS 20
  • FIGURE 5 KOREA AESTHETIC MARKET: COMPANY RESEARCH ANALYSIS 20
  • FIGURE 6 KOREA AESTHETIC MARKET: INTERVIEW DEMOGRAPHICS 21
  • FIGURE 7 KOREA AESTHETIC MARKET: MARKET END USER COVERAGE GRID 23
  • FIGURE 8 KOREA AESTHETIC MARKET: DBMR MARKET POSITION GRID 24
  • FIGURE 9 KOREA AESTHETIC MARKET: VENDOR SHARE ANALYSIS 26
  • FIGURE 10 KOREA AESTHETIC MARKET: SEGMENTATION 29
  • FIGURE 11 LESSER COST OF TREATMENT FOR MEDICAL AESTHETICS AS COMPARED TO OTHER COUNTRIES ARE EXPECTED TO DRIVE THE GROWTH OF THE KOREA AESTHETIC MARKET FROM 2023 TO 2030 30
  • FIGURE 12 NON ENERGY BASED AESTHETIC DEVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE KOREA AESTHETIC MARKET IN 2023 AND 2030 30
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE KOREA AESTHETIC MARKET 36
  • FIGURE 14 KOREA AESTHETIC MARKET: BY DEVICES, 2022 45
  • FIGURE 15 KOREA AESTHETIC MARKET: BY APPLICATION, 2022 50
  • FIGURE 16 KOREA AESTHETIC MARKET: BY BRANDS, 2022 56
  • FIGURE 17 KOREA AESTHETIC MARKET: BY GENDER, 2022 61
  • FIGURE 18 KOREA AESTHETIC MARKET: BY END USER, 2022 64
  • FIGURE 19 KOREA AESTHETIC MARKET: BY DISTRIBUTION CHANNEL, 2022 67
  • FIGURE 20 KOREA AESTHETIC MARKET: COMPANY SHARE 2022 (%) 69
  • FIGURE 21 KOREA AESTHETIC MARKET (WITHOUT GLOBAL BASE): COMPANY SHARE 2022 (%) 70